Lucid Diligence Brief: Basata $21 million Series A
Lucid Diligence Brief: Basata $21 million Series A Professional audiences only.…
Lucid Diligence Brief: Latus Bio $97 million Series A
Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m
Lucid Diligence Brief: T-Therapeutics Series A extension to $91m Professional…
Lucid Diligence Brief: AAVantgarde Bio $141M Series B
Lucid Diligence Brief: AAVantgarde Bio $141M Series B Professional audiences…